China Sleep-Wake Disorder Market Size to Reach $3.4 Billion by 2035

China sleep-wake disorder market is projected to grow from $1.8 billion in 2025 and is projected to reach $3.4 billion by 2035, growing at a CAGR of 6.4% during the forecast period 2026-2035. The China sleep-wake disorder market is witnessing steady development driven by increasing recognition of sleep-related health conditions and their long-term impact on overall well-being. Growing urbanization, changing lifestyles, and higher levels of occupational stress are contributing to a rising incidence of sleep disturbances. Healthcare providers are placing greater emphasis on early diagnosis through improved screening practices and sleep study adoption. Advancements in clinical tools and monitoring technologies are supporting more accurate identification of sleep-wake disorders. In addition, expanding awareness among patients is encouraging earlier consultation and treatment-seeking behavior. These factors are collectively strengthening the overall demand for diagnostic and therapeutic solutions in the market.

Browse the full report description of “China Sleep-Wake Disorder Market Size, Share & Trends Analysis By Disorder Type (Insomnia, Hypersomnia, Sleep Apnea, Circadian Rhythm Sleep-Wake Disorders, Parasomnias, Dyssomnias, and Others), By Treatment Type (Pharmacological Therapy, Behavioral Therapy, Light Therapy, Device-Based Therapy, and Others), By Diagnosis & Management Approach (Polysomnography & Sleep Studies, Actigraphy-Based Monitoring, Clinical Evaluation & Screening Tools, and Remote/Digital Sleep Monitoring Solutions), and By Application (Hospitals, Home Care Settings, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/china-sleep-wake-disorder-market

The market is also being shaped by ongoing improvements in treatment approaches and healthcare infrastructure across China. Increased integration of digital health solutions and remote monitoring systems is enhancing patient management and follow-up care. Pharmaceutical and medical device innovations are supporting a shift toward more targeted and personalized treatment strategies. Hospitals and specialized sleep clinics are expanding their capabilities to address complex sleep-related conditions. At the same time, supportive healthcare policies and investments in modern medical technologies are improving access to care. These developments are expected to sustain the evolution of the sleep-wake disorder treatment landscape in the country.

Competitive Landscape of the Sleep-Wake Disorder Market

The key players in the sleep-wake disorder market are Shanghai Fosun Pharmaceutical Group Co. Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Shanghai Pharmaceuticals Holding Co. Ltd., Sinopharm Group Co. Ltd., and BeiGene Ltd., among others. The competitive landscape is characterized by strong participation from established domestic pharmaceutical companies with diversified neuroscience and central nervous system portfolios. These players are actively engaged in developing and supplying therapies aimed at addressing various sleep-related and neurological conditions. Continuous investment in research and development is supporting the introduction of improved treatment options and formulations. In addition, expansion of distribution networks and collaboration with healthcare providers is enhancing access across urban and semi-urban regions. The overall focus remains on strengthening clinical capabilities and improving patient management within the sleep-wake disorder segment.

• In August 2025, Eisai Co., Ltd. introduced DAYVIGO (lemborexant) in the Chinese market following regulatory approval by the National Medical Products Administration. The product is indicated for adult insomnia involving sleep onset and sleep maintenance difficulties, representing an orexin receptor antagonist approach targeting sleep-wake regulation mechanisms.

• In June 2025, Simcere Pharmaceutical Group expanded its neuroscience portfolio in China through the approval and introduction of QUVIVIQ (daridorexant hydrochloride) for adult insomnia management. The therapy is part of the dual orexin receptor antagonist class and is used for patients experiencing difficulties in sleep initiation and maintenance. Its availability was supported by clinical evaluation conducted in both domestic and international study settings, strengthening evidence-based adoption.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Disorder Type
  • By Treatment Type
  • By Diagnosis & Management Approach
  • By Application
• Competitive Landscape - Shanghai Fosun Pharmaceutical Group Co. Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Shanghai Pharmaceuticals Holding Co. Ltd., Sinopharm Group Co. Ltd., and BeiGene Ltd.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

China Sleep-Wake Disorder Market Report Segment

By Disorder Type

• Insomnia
• Hypersomnia
• Sleep Apnea
• Circadian Rhythm Sleep-Wake Disorders
• Parasomnias
• Dyssomnias
• Others

By Treatment Type

• Pharmacological Therapy
• Behavioral Therapy
• Light Therapy
• Device-Based Therapy
• Others

By Diagnosis & Management Approach

• Polysomnography & Sleep Studies
• Actigraphy-Based Monitoring
• Clinical Evaluation & Screening Tools
• Remote / Digital Sleep Monitoring Solutions

By Application

• Hospitals
• Home Care Settings
• Others

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/china-sleep-wake-disorder-market